Program
Ibuprofen
Also written as “ibuprofen”, “Intravenous ibuprofen” and “Ibuprofen/acetaminophen”.
Its studies are mostly in Pain · Pain, Postoperative · Osteoarthritis · Fever · Osteoarthritis, Knee, led by 36 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 150 open or running | phase 4since Aug 22, 2008 | Aug 22, 2008 | none ahead |
| Cumberland Pharmaceuticals | 90 open or running | phase 4since Apr 12, 2011 | Sep 22, 2005 | none ahead |
| Johnson & Johnson | 70 open or running | phase 4since Oct 14, 2005 | Oct 14, 2005 | none ahead |
| Boehringer Ingelheim | 60 open or running | phase 3since Aug 22, 2013 | Jul 26, 2010 | none ahead |
| Dr. Reddy's Laboratories | 60 open or running | phase 1since Jan 20, 2010 | Jan 20, 2010 | none ahead |
| Reckitt | 60 open or running | phase 3since Oct 26, 2010 | Oct 26, 2010 | none ahead |
| AFT Pharmaceuticals | 51 open or running | phase 3since Aug 16, 2011 | Apr 14, 2010 | Mar 2027phase 3 · NCT07225634 |
| Strategic Science & Technologies | 40 open or running | phase 3since Oct 11, 2012 | Oct 11, 2012 | none ahead |
| Angelini Pharma | 30 open or running | phase 1since Jun 17, 2015 | Jun 17, 2015 | none ahead |
| GlaxoSmithKline | 30 open or running | phase 4since Mar 28, 2013 | Sep 5, 2006 | none ahead |
| Hypera Pharma | 30 open or running | phase 4since May 20, 2011 | Jul 28, 2010 | none ahead |
| Pierre Fabre | 30 open or running | phase 3since Feb 5, 2013 | Feb 10, 2012 | none ahead |
| Amgen | 20 open or running | phase 4since Mar 20, 2012 | Mar 19, 2007 | none ahead |
| Laboratorios Silanes S.A. de C.V. | 20 open or running | phase 3since Jul 18, 2024 | Jun 15, 2022 | none ahead |
| medherant-ltd | 20 open or running | phase 1since Aug 16, 2018 | Aug 16, 2018 | none ahead |
| Orion Corporation, Orion Pharma | 20 open or running | phase 3since Mar 22, 2012 | Mar 22, 2012 | none ahead |
| overseas-pharmaceuticals-ltd | 21 open or running | phase 3since Dec 20, 2021 | Feb 4, 2021 | none ahead |
| oxford-pharmascience-ltd | 20 open or running | phase 1since Aug 5, 2015 | Aug 5, 2015 | none ahead |
| perrigo-company | 20 open or running | phase 1since Dec 5, 2008 | Dec 5, 2008 | none ahead |
| Ache Laboratorios Farmaceuticos | 10 open or running | phase 3since Mar 8, 2016 | Mar 8, 2016 | none ahead |
| biochemics-inc | 10 open or running | phase 2since Dec 15, 2011 | Dec 15, 2011 | none ahead |
| biomendi-s-a-u | 10 open or running | phase 3since Sep 25, 2014 | Sep 25, 2014 | none ahead |
| futura-medical-developments-ltd | 10 open or running | phase 1since Jan 20, 2016 | Jan 20, 2016 | none ahead |
| future-sciene-technology | 10 open or running | phase 4since Dec 11, 2014 | Dec 11, 2014 | none ahead |
| HALEON | 10 open or running | phase 1since Dec 12, 2025 | Dec 12, 2025 | none ahead |
| Hamad Medical | 10 open or running | early phase 1since Oct 7, 2019 | Oct 7, 2019 | none ahead |
| laborato-rio-teuto-brasileiro-s-a | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| lahore-medical-research-center-llp | 10 open or running | phase 3since Feb 23, 2024 | Feb 23, 2024 | none ahead |
| Menarini Group | 10 open or running | phase 1since Jun 17, 2025 | Jun 17, 2025 | none ahead |
| Merck | 10 open or running | phase 1since Nov 28, 2007 | Nov 28, 2007 | none ahead |
| qc-kinetix-llc | 10 open or running | phase 2since Feb 6, 2023 | Feb 6, 2023 | none ahead |
| Sanofi | 10 open or running | phase 3since Aug 31, 2011 | Aug 31, 2011 | none ahead |
| scolr-pharma-inc | 10 open or running | phase 3since Jun 26, 2008 | Jun 26, 2008 | none ahead |
| simbec-research | 10 open or running | phase 1since Sep 16, 2014 | Sep 16, 2014 | none ahead |
| spherium-biomed | 10 open or running | phase 2since Nov 10, 2015 | Nov 10, 2015 | none ahead |
| x-pert-med-gmbh | 10 open or running | phase 1since Jan 22, 2010 | Jan 22, 2010 | none ahead |
Also a collaborator on its studies: premier-research-group-plc, parexel, aptuit, cross-research-s-a, pharma-consulting-group-ab, pivotal-s-l and aaipharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Nov 3, 2011.
- Oct 25, 2018Phase 3 study in PainPfizer · NCT03722238 · 613 enrolled · United States
- Dec 17, 2018Phase 3 study in PainReckitt · NCT03785756 · 280 enrolled · United States
- Oct 7, 2019Hamad Medical's first study: early phase 1 study in FeverNew to Hamad MedicalHamad Medical · NCT04123717 · 147 enrolled · Qatar
- Feb 4, 2021overseas-pharmaceuticals-ltd's first study: phase 1 study in Chronic PainNew to overseas-pharmaceuticals-ltdoverseas-pharmaceuticals-ltd · NCT05329454 · 30 enrolled · China
- Aug 3, 2021Phase 3 study in Musculoskeletal PainHypera Pharma · NCT05013567 · 300 enrolled
- Dec 20, 2021Phase 3 study in Osteoarthritisoverseas-pharmaceuticals-ltd · NCT05318521 · 500 enrolled · United States, Taiwan
- Jun 15, 2022Laboratorios Silanes S.A. de C.V.'s first study: phase 1 study in PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT05428306 · 42 enrolled · Mexico
- Jul 27, 2022Phase 3 study in Tooth, ImpactedReckitt · NCT05484401 · 294 enrolled · United States
- Feb 6, 2023qc-kinetix-llc's first study: phase 2 study in Osteoarthritis, KneeNew to qc-kinetix-llcqc-kinetix-llc · NCT05742763 · United States
- Feb 23, 2024lahore-medical-research-center-llp's first study: phase 3 study in Primary DysmenorrheaNew to lahore-medical-research-center-llplahore-medical-research-center-llp · NCT06317064 · 40 enrolled · Pakistan
- Jul 18, 2024Phase 3 study in Common ColdLaboratorios Silanes S.A. de C.V. · NCT06531707 · 177 enrolled · Mexico
- Jun 17, 2025Menarini Group's first study: phase 1 study in Healthy Male and Female SubjectsNew to Menarini GroupMenarini Group · NCT07036861 · 74 enrolled · Lithuania
- Oct 30, 2025Phase 3 study in Acute PainAFT Pharmaceuticals · NCT07225634 · 60 planned · Hungary
- Dec 12, 2025HALEON's first study: phase 1 study in BioequivalenceNew to HALEONHALEON · NCT07345130 · 68 enrolled · United States
Ahead
- Mar 2027Primary completion: phase 3 study in Acute PainAFT Pharmaceuticals · NCT07225634
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
The newest 60 of 101 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07345130Bioequivalence · United States | 1 | Completed | HALEON | Feb 3, 2026 | 68 |
| NCT07225634Acute Pain · Hungary | 3 | Recruiting | AFT Pharmaceuticals | Mar 2027 | 60 |
| NCT07036861Healthy Male and Female Subjects · Lithuania | 1 | Completed | Menarini Group | Apr 8, 2024 | 74 |
| NCT06531707Common Cold · Mexico | 3 | Completed | Laboratorios Silanes S.A. de C.V. | Jan 20, 2025 | 177 |
| NCT06317064Primary Dysmenorrhea · Pakistan | 3 | Completed | lahore-medical-research-center-llp | Oct 31, 2024 | 40 |
| NCT05742763Osteoarthritis, Knee · United States | 2 | Withdrawn | qc-kinetix-llc | Oct 7, 2024 | 0 |
| NCT05484401Tooth, Impacted · United States | 3 | Completed | Reckitt | Jun 15, 2023 | 294 |
| NCT05428306Pain · Mexico | 1 | Completed | Laboratorios Silanes S.A. de C.V. | Nov 6, 2018 | 42 |
| NCT05318521Osteoarthritis · United States, Taiwan | 3 | Active, not recruiting | overseas-pharmaceuticals-ltd | Aug 12, 2022 | 500 |
| NCT05013567Musculoskeletal Pain | 3 | UNKNOWN | Hypera Pharma | May 2023 | 300 |
| NCT05329454Chronic Pain · China | 1 | Completed | overseas-pharmaceuticals-ltd | Feb 6, 2021 | 30 |
| NCT04123717Fever · Qatar | Early 1 | Completed | Hamad Medical | Mar 7, 2024 | 147 |
| NCT03785756Pain · United States | 3 | Completed | Reckitt | Feb 20, 2020 | 280 |
| NCT03722238Pain · United States | 3 | Terminated | Pfizer | Oct 28, 2019 | 613 |
| NCT03694587Healthy · Bulgaria | 1 | Completed | medherant-ltd | Oct 18, 2018 | 16 |
| NCT03639571Healthy · Bulgaria | 1 | Completed | medherant-ltd | Oct 25, 2018 | 33 |
| NCT03658720Healthy · United Kingdom | – | Terminated | Reckitt | Dec 21, 2017 | 29 |
| NCT03496324Bioequivalence of the Test Formulation | 1 | Completed | Reckitt | May 6, 2016 | 24 |
| NCT03497715Healthy Subjects | 1 | Terminated | Reckitt | Jul 30, 2015 | 6 |
| NCT02974361Pharmacokinetics · United Kingdom | 1 | Completed | oxford-pharmascience-ltd | Apr 28, 2017 | 30 |
| NCT03003000Back Pain · Germany, Russian Federation | 3 | Completed | Boehringer Ingelheim | Sep 24, 2017 | 635 |
| NCT02963701Healthy Volunteers · South Africa | 1 | Completed | Boehringer Ingelheim | Jan 31, 2017 | 56 |
| NCT02902302Healthy · Switzerland | 1 | Completed | Angelini Pharma | Jun 2016 | 60 |
| NCT02902289Healthy · Switzerland | 1 | Completed | Angelini Pharma | Jul 2016 | 60 |
| NCT02863575Pain · United States | 3 | Completed | Pfizer | Apr 6, 2018 | 374 |
| NCT02761980Fever · United States | 3 | Completed | Pfizer | Dec 6, 2017 | 290 |
| NCT02904304Common Cold · Brazil | 3 | Suspended | Ache Laboratorios Farmaceuticos | Jul 2021 | 150 |
| NCT02689063Pain, Postoperative · United States | 3 | Completed | AFT Pharmaceuticals | Jun 30, 2017 | 276 |
| NCT02666846Pain · United Kingdom | 1 | Completed | futura-medical-developments-ltd | May 2015 | 60 |
| NCT02912650Pain · United States | 3 | Completed | Pfizer | Jun 2016 | 568 |
| NCT02602483Temporomandibular Joint Disorders · Spain | 2 | Completed | spherium-biomed | Dec 2016 | 96 |
| NCT02583399Pain · United States | 4 | Completed | Cumberland Pharmaceuticals | Jul 2, 2019 | 30 |
| NCT02597634Delayed Onset Muscle Soreness, DOMS · United States | 3 | Completed | Strategic Science & Technologies | Oct 2016 | 156 |
| NCT02521207Gastroduodenal Erosions · United Kingdom | 1 | Completed | oxford-pharmascience-ltd | Aug 2015 | 53 |
| NCT02482155Healthy · Switzerland | 1 | Completed | Angelini Pharma | Mar 2015 | 24 |
| NCT02339129Delayed Onset Muscle Soreness · United States | 2 | Completed | Strategic Science & Technologies | Feb 2015 | 72 |
| NCT02327338Pain · United States | 4 | Completed | future-sciene-technology | Feb 2015 | 90 |
| NCT02294019Patient Compliance · United States | 3 | Completed | Pfizer | May 2015 | 738 |
| NCT02254525Pain, Postoperative · Spain | 3 | Terminated | biomendi-s-a-u | Jun 2014 | 231 |
| NCT02256423Healthy Volunteer Study · United Kingdom | 1 | Completed | simbec-research | Aug 2014 | 24 |
| NCT02183051Pain | 2 | Completed | Boehringer Ingelheim | Oct 1998 | 381 |
| NCT01986660Healthy · United States | 1 | Completed | Strategic Science & Technologies | Oct 2013 | 14 |
| NCT01929031Pain, Postoperative · United States | 3 | Completed | Boehringer Ingelheim | Mar 2014 | 562 |
| NCT01901393Pain · United States | 4 | Completed | Cumberland Pharmaceuticals | Aug 2014 | 100 |
| NCT01879371Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jul 2013 | 36 |
| NCT01859377Healthy Volunteers · Belgium | 1 | Completed | Pierre Fabre | Jun 2013 | 26 |
| NCT01822665Gastrointestinal Mucosal Damage · United States | 4 | Completed | GlaxoSmithKline | Jul 2012 | 28 |
| NCT01785862Respiratory Tract Infections · France, Germany, Latvia and more | 3 | Completed | Pierre Fabre | Jun 2013 | 427 |
| NCT01771822Pain · United States | 1 | Completed | Pfizer | Feb 2013 | 50 |
| NCT01874626Lymphoma, Follicular · United States | 3 | Completed | Strategic Science & Technologies | Jan 2014 | 305 |
| NCT01789606Agnosia · United States | 3 | Completed | Pfizer | Jun 3, 2013 | 1,083 |
| NCT01650519Arthroscopic Knee Surgery · United States | 4 | Completed | Cumberland Pharmaceuticals | Dec 2012 | 51 |
| NCT01563289Pain · Finland | 3 | Completed | Orion Corporation, Orion Pharma | Jul 2012 | 62 |
| NCT01562717Pain · Finland | 3 | Completed | Orion Corporation, Orion Pharma | Oct 2012 | 62 |
| NCT01563185Arthritis, Juvenile · United States | 4 | Completed | Amgen | Mar 2015 | 12 |
| NCT01559259Pain · United States | 2 | Completed | Pfizer | Sep 13, 2012 | 394 |
| NCT01555476Pain · Sweden | 1 | Completed | Johnson & Johnson | Mar 2012 | 32 |
| NCT01535079Respiratory Tract Infections · France, Germany, United Kingdom | 2 | Completed | Pierre Fabre | Nov 2012 | 186 |
| NCT01496326Osteoarthritis · Switzerland | 2 | Completed | biochemics-inc | Aug 2011 | 75 |
| NCT01466517Healthy · Brazil | 4 | Completed | Pfizer | Nov 2011 | 70 |
How it is read
Names in the registry
- “Ibuprofen”, 40 entries
- “ibuprofen”, 10 entries
- “Intravenous ibuprofen”, 5 entries
- “Ibuprofen/acetaminophen”, 4 entries
- “ibuprofen + caffeine”, 3 entries
Codes read as this program: SST0225.
Conditions, from the studies’ own filings
- Pain, 28 studies
- Pain, Postoperative, 6 studies
- Osteoarthritis, 5 studies
- Fever, 5 studies
- Osteoarthritis, Knee, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.